Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care

Patients will report taking new diabetes meds during admission histories as more GLP-1 agonists and SGLT2 inhibitors hit the market...

Exclusive Subscriber Content

  • Best in class medication learning
  • Concise recommendations
  • Hundreds of practical resources

Subscribe Now Learn More

Login to access this content.

Login